HighTower Advisors
PSTV

HighTower Advisors’s Plus Therapeutics PSTV Stock Holding History

HighTower Advisors’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-640
Closed -$8.2K – 3905
2025
Q4 		$8.2K Buy
+640
New +$9.65K ﹤0.01% 3639
2018
Q2 		– Hold
0
– -$5K – 2357
2018
Q1 		– Hold
0
– – – 2121
2017
Q4 		– Hold
0
– – – 2209
2017
Q3 		– Hold
0
– – – 2164
2017
Q2 		– Hold
0
– – – 2083
2017
Q1 		– Hold
0
– – – 1958

Other funds holding PSTV

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

HighTower Advisors's PSTV Position: Q1 2026 in Review

HighTower Advisors sold out of Plus Therapeutics (PSTV) in Q1 2026, closing a stake of 640 shares — an estimated $8.2K sold.

HighTower Advisors first reported a position in PSTV in Q4 2025 and held it in 1 quarter. The position peaked at $8.2K in Q4 2025. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • HighTower Advisors reported no remaining Plus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HighTower Advisors sold 640 Plus Therapeutics shares in Q1 2026, an estimated $8.2K.
  • HighTower Advisors first reported a position in Plus Therapeutics in Q4 2025 and held it in 1 quarter.
  • HighTower Advisors's Plus Therapeutics position peaked at $8.2K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.